Cargando…

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging noninvasive approach for the treatment of oligometastases. Limited prospective evidence is available in breast cancer. OBJECTIVES: To determine the safety and feasibility of single fraction SABR for patients with bone only oli...

Descripción completa

Detalles Bibliográficos
Autores principales:	David, Steven, Tan, Jennifer, Savas, Peter, Bressel, Mathias, Kelly, Dianne, Foroudi, Farshad, Loi, Sherene, Siva, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375645/ https://www.ncbi.nlm.nih.gov/pubmed/31734589 http://dx.doi.org/10.1016/j.breast.2019.10.016

Ejemplares similares

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy
por: Siva, Shankar, et al.
Publicado: (2013)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
por: Pryor, David, et al.
Publicado: (2021)

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists
por: Li, Shan, et al.
Publicado: (2020)

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma
por: Reynolds, Hayley M., et al.
Publicado: (2018)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
por: Olson, Robert, et al.
Publicado: (2018)

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
por: Hardcastle, Nicholas, et al.
Publicado: (2021)

Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT
por: Jackson, Price, et al.
Publicado: (2014)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
por: Ghandourh, Wsam, et al.
Publicado: (2022)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers
por: Anand, Anil Kumar, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
por: Boda-Heggemann, Judit, et al.
Publicado: (2012)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care
por: Raymakers, Adam J. N., et al.
Publicado: (2021)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer
por: Wijetunga, N. Ari, et al.
Publicado: (2021)

Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience
por: Sánchez-Iglesias, Ángel L., et al.
Publicado: (2022)

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
por: Webking, Samantha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9rjahj2hua6f4i0p3s6a8uq91r